Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

240 Pages·2015·5.687 MB·English

by  CLSI

January 2015
M100-S25
Performance Standards for Antimicrobial
Susceptibility Testing; Twenty-Fifth
Informational Supplement
This document provides updated tables for the Clinical and
Laboratory Standards Institute antimicrobial susceptibility testing
standards M02-A12, M07-A10, and M11-A8.
An informational supplement for global application developed through the Clinical and Laboratory Standards Institute
consensus process.
Clinical and Laboratory Standards Institute
Setting the standard for quality in clinical laboratory testing around the world.
The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings
together the varied perspectives and expertise of the worldwide laboratory community for the advancement of
a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory
standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and
global applicability.

Consensus Process
Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the
development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the
participants in the development of a consensus document have considered and resolved all relevant objections
and accept the resulting agreement.

Commenting on Documents
CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies,
procedures, methods, and protocols affecting the laboratory or health care.
CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as
participants in the reviewing and commenting process. At the end of each comment period, the committee that
developed the document is obligated to review all comments, respond in writing to all substantive comments,
and revise the draft document as appropriate.
Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on
any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process
If it is believed that an objection has not been adequately addressed, the process for appeals is documented in
the CLSI Standards Development Policies and Process document.
All comments and responses submitted on draft and published documents are retained on file at CLSI and are
available upon request.
Get Involved—Volunteer!
Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get
involved in the revision process? Or maybe you see a need to develop a new document for an emerging
technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and
talents to improve the standards that affect your own work, you will play an active role in improving public
health across the globe.
For further information on committee participation or to submit comments, contact CLSI.
Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
[email protected]
Vol. 35 No. 3 M100-S25
Performance Standards for Antimicrobial Susceptibility Testing;
Twenty-Fifth Informational Supplement
Abstract
The supplemental information presented in this document is intended for use with the antimicrobial
susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute
(CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility
Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial
Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and
M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—
Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11)
test procedures for aerobic and anaerobic bacteria.
Clinicians depend heavily on information from the clinical microbiology laboratory for treatment of their
seriously ill patients. The clinical importance of antimicrobial susceptibility test results requires that these
tests be performed under optimal conditions and that laboratories have the capability to provide results for
the newest antimicrobial agents.
The tabular information presented here represents the most current information for drug selection,
interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and
M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since
the previous edition appear in boldface type.)
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility
Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25 (ISBN 1-56238-989-0
[Print]; ISBN 1-56238-990-4 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley
Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2015.
The data in the interpretive tables in this supplement are valid only if the
methodologies in M02-A12—Performance Standards for Antimicrobial Disk
Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods
for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow
Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for
Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—
Eighth Edition are followed.
1
January 2015 M100-S25

2
ISBN 1-56238-989-0 (Print) M100-S25
ISBN 1-56238-990-4 (Electronic) Vol. 35 No. 3
ISSN 1558-6502 (Print) Replaces M100-S24
ISSN 2162-2914 (Electronic) Vol. 34No. 1
Performance Standards for Antimicrobial Susceptibility Testing;
Twenty-Fifth Informational Supplement

Volume 35 Number 3

Jean B. Patel, PhD, D(ABMM)
Franklin R. Cockerill III, MD
Patricia A. Bradford, PhD
George M. Eliopoulos, MD
Janet A. Hindler, MCLS, MT(ASCP)
Stephen G. Jenkins, PhD, D(ABMM), F(AAM)
James S. Lewis II, PharmD
Brandi Limbago, PhD
Linda A. Miller, PhD
David P. Nicolau, PharmD, FCCP, FIDSA
Mair Powell, MD, FRCP, FRCPath
Jana M. Swenson, MMSc
Maria M. Traczewski, BS, MT(ASCP)
John D. Turnidge, MD
Melvin P. Weinstein, MD
Barbara L. Zimmer, PhD
January 2015 M100-S25

Copyright ©2015 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of
content from a CLSI copyrighted standard, guideline, companion product, or other material requires
express written consent from CLSI. All rights reserved. Interested parties may send permission requests to
[email protected].

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of
this publication for use in its laboratory procedure manual at a single site. To request permission to use
this publication in any other manner, e-mail [email protected].

Suggested Citation

CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational
Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

Twenty-Fifth Informational Supplement Seventeenth Informational Supplement
January 2015 January 2007

Twenty-Fourth Informational Supplement Sixteenth Informational Supplement
January 2014 January 2006

Twenty-Third Informational Supplement Fifteenth Informational Supplement
January 2013 January 2005

Twenty-Second Informational Supplement Fourteenth Informational Supplement
January 2012 January 2004

Twenty-First Informational Supplement Thirteenth Informational Supplement
January 2011 January 2003

Twentieth Informational Supplement (Update) Twelfth Informational Supplement
June 2010 January 2002

Twentieth Informational Supplement Eleventh Informational Supplement
January 2010 January 2001

Nineteenth Informational Supplement Tenth Informational Supplement
January 2009 January 2000

Eighteenth Informational Supplement Ninth Informational Supplement
January 2008 January 1999

ISBN 1-56238-989-0 (Print)
ISBN 1-56238-990-4 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)
4
Vol. 35 No. 3 M100-S25

Committee Membership

Consensus Committee on Microbiology

Richard B. Thomson, Jr., PhD, Patrick R. Murray, PhD John D. Turnidge, MD
D(ABMM), FAAM BD Diagnostic Systems SA Pathology at Women’s and
Chairholder USA Children’s Hospital
Evanston Hospital, NorthShore Australia
University HealthSystem Jean B. Patel, PhD, D(ABMM)
USA Centers for Disease Control and Jeffrey L. Watts, PhD, RM(NRCM)
Prevention Zoetis
John H. Rex, MD, FACP USA USA
Vice-Chairholder
AstraZeneca Pharmaceuticals Kerry Snow, MS, MT(ASCP) Nancy L. Wengenack, PhD,
USA FDA Center for Drug Evaluation and D(ABMM)
Research Mayo Clinic
Thomas R. Fritsche, MD, PhD USA USA
Marshfield Clinic
USA Barbara L. Zimmer, PhD
Siemens Healthcare Diagnostics Inc.
USA

Subcommittee on Antimicrobial Susceptibility Testing

Jean B. Patel, PhD, D(ABMM) Janet A. Hindler, MCLS, MT(ASCP) David P. Nicolau, PharmD, FCCP,
Chairholder UCLA Medical Center FIDSA
Centers for Disease Control and USA Hartford Hospital
Prevention USA
USA Stephen G. Jenkins, PhD, D(ABMM),
F(AAM) Mair Powell, MD, FRCP, FRCPath
Franklin R. Cockerill III, MD New York Presbyterian Hospital MHRA
Vice-Chairholder USA United Kingdom
Mayo Clinic
USA James S. Lewis II, PharmD John D. Turnidge, MD
Oregon Health and Science University SA Pathology at Women’s and
Patricia A. Bradford, PhD USA Children’s Hospital
AstraZeneca Pharmaceuticals Australia
USA Brandi Limbago, PhD
Centers for Disease Control and Melvin P. Weinstein, MD
George M. Eliopoulos, MD Prevention Robert Wood Johnson University
Beth Israel Deaconess Medical Center USA Hospital
USA USA
Linda A. Miller, PhD
GlaxoSmithKline Barbara L. Zimmer, PhD
USA Siemens Healthcare Diagnostics Inc.
USA
Acknowledgment

CLSI, the Consensus Committee on Microbiology, and the Subcommittee on Antimicrobial Susceptibility
Testing gratefully acknowledge the following volunteers for their important contributions to the
development of this document:

Jana M. Swenson, MMSc Maria M. Traczewski, BS,
USA MT(ASCP)
The Clinical Microbiology
Institute
USA

5
January 2015 M100-S25

Working Group on AST Breakpoints

George M. Eliopoulos, MD David P. Nicolau, PharmD, FCCP, Simone Shurland
Co-Chairholder FIDSA FDA Center for Devices and
Beth Israel Deaconess Medical Hartford Hospital Radiological Health
Center USA USA
USA
Mair Powell, MD, FRCP, Lauri D. Thrupp, MD
James S. Lewis II, PharmD FRCPath UCI Medical Center (University
Co-Chairholder MHRA of California, Irvine)
Oregon Health and Science United Kingdom USA
University
USA Michael Satlin, MD, MS Hui Wang, PhD
Weill Cornell Medical College Peking University People’s
Karen Bush, PhD USA Hospital
Indiana University China
USA Paul C. Schreckenberger, PhD,
D(ABMM), F(AAM) Melvin P. Weinstein, MD
Marcelo F. Galas Loyola University Medical Center Robert Wood Johnson University
National Institute of Infectious USA Hospital
Diseases USA
Argentina Audrey N. Schuetz, MD, MPH,
D(ABMM) Matthew A. Wikler, MD, MBA,
Amy J. Mathers, MD Weill Cornell Medical FIDSA
University of Virginia Medical College/NewYork-Presbyterian The Medicines Company
Center Hospital USA
USA USA
Barbara L. Zimmer, PhD
Siemens Healthcare Diagnostics
Inc.
USA

Working Group on Methodology

Stephen G. Jenkins, PhD, Laura M. Koeth, MT(ASCP) Susan Sharp, PhD, D(ABMM),
D(ABMM), F(AAM) Laboratory Specialists, Inc. F(AAM)
Co-Chairholder USA American Society for Microbiology
New York Presbyterian Hospital USA
USA Sandra S. Richter, MD, D(ABMM)
Cleveland Clinic Ribhi M. Shawar, PhD, D(ABMM)
Brandi Limbago, PhD USA FDA Center for Devices and
Co-Chairholder Radiological Health
Centers for Disease Control and Darcie E. Roe-Carpenter, PhD, CIC, USA
Prevention CEM
USA Siemens Healthcare Diagnostics John D. Turnidge, MD
Inc. SA Pathology at Women’s and
Seth T. Housman, PharmD, MPA USA Children’s Hospital
Hartford Hospital Australia
USA Katherine Sei
Siemens Healthcare Diagnostics
Romney M. Humphries, PhD, Inc.
D(ABMM) USA
UCLA Medical Center
USA

6
Vol. 35 No. 3 M100-S25

Working Group on Quality Control

Steven D. Brown, PhD, ABMM Stephen Hawser, PhD Ross Mulder, MT(ASCP)
Co-Chairholder IHMA Europe Sàrl bioMérieux, Inc.
USA Switzerland USA

Sharon K. Cullen, BS, RAC Janet A. Hindler, MCLS, MT(ASCP) Susan D. Munro, MT(ASCP), CLS
Co-Chairholder UCLA Medical Center USA
Siemens Healthcare Diagnostics Inc. USA
USA Robert P. Rennie, PhD
Denise Holliday, MT(ASCP) Provincial Laboratory for Public
William B. Brasso BD Diagnostic Systems Health
BD Diagnostic Systems USA Canada
USA
Michael D. Huband Frank O. Wegerhoff, PhD,
Patricia S. Conville, MS, MT(ASCP) AstraZeneca Pharmaceuticals MSc(Epid), MBA
FDA Center for Devices and Radiological USA USA
Health
USA Erika Matuschek, PhD Mary K. York, PhD, ABMM
ESCMID MKY Microbiology Consulting
Robert K. Flamm, PhD Sweden USA
JMI Laboratories
USA

Working Group on Text and Tables

Jana M. Swenson, MMSc Linda M. Mann, PhD, D(ABMM) Dale A. Schwab, PhD, D(ABMM)
Co-Chairholder USA Quest Diagnostics Nichols Institute
USA USA
Melissa B. Miller, PhD, D(ABMM)
Maria M. Traczewski, BS, MT(ASCP) UNC Hospitals Richard B. Thomson, Jr., PhD,
Co-Chairholder USA D(ABMM), FAAM
The Clinical Microbiology Institute Evanston Hospital, NorthShore
USA Susan D. Munro, MT(ASCP), CLS University HealthSystem
USA USA
Janet A. Hindler, MCLS, MT(ASCP)
UCLA Medical Center Nancy E. Watz, MS, MT(ASCP),
Flavia Rossi, MD
USA CLS
University of São Paulo
Stanford Hospital and Clinics
Brazil
Peggy Kohner, BS, MT(ASCP) USA

Mayo Clinic
Jeff Schapiro, MD
USA Mary K. York, PhD, ABMM
Kaiser Permanente
MKY Microbiology Consulting
Dyan Luper, BS, MT(ASCP)SM, MB USA USA
BD Diagnostic Systems
USA

Staff

Clinical and Laboratory Megan L. Tertel, MA
Standards Institute Editorial Manager
USA
Joanne P. Christopher, MA
Luann Ochs, MS Editor
Senior Vice President – Operations
Patrice E. Polgar
Tracy A. Dooley, MLT(ASCP) Editor
Project Manager

7
January 2015 M100-S25

8